MX2024007460A - Tratamiento de afecciones pulmonares con inhibidores de la subunidad alfa 1 de integrina (itga1). - Google Patents

Tratamiento de afecciones pulmonares con inhibidores de la subunidad alfa 1 de integrina (itga1).

Info

Publication number
MX2024007460A
MX2024007460A MX2024007460A MX2024007460A MX2024007460A MX 2024007460 A MX2024007460 A MX 2024007460A MX 2024007460 A MX2024007460 A MX 2024007460A MX 2024007460 A MX2024007460 A MX 2024007460A MX 2024007460 A MX2024007460 A MX 2024007460A
Authority
MX
Mexico
Prior art keywords
lung disease
itga1
inhibitors
treatment
subunit alpha
Prior art date
Application number
MX2024007460A
Other languages
English (en)
Spanish (es)
Inventor
Aris Baras
Goncalo Abecasis
Manuel Allen Revez Ferreira
Katherine Siminovitch
Julie E Horowitz
Maria Cristina Suciu
Original Assignee
Regeneron Pharma
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Regeneron Pharma filed Critical Regeneron Pharma
Publication of MX2024007460A publication Critical patent/MX2024007460A/es

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N15/00—Mutation or genetic engineering; DNA or RNA concerning genetic engineering, vectors, e.g. plasmids, or their isolation, preparation or purification; Use of hosts therefor
    • C12N15/09—Recombinant DNA-technology
    • C12N15/11—DNA or RNA fragments; Modified forms thereof; Non-coding nucleic acids having a biological activity
    • C12N15/113—Non-coding nucleic acids modulating the expression of genes, e.g. antisense oligonucleotides; Antisense DNA or RNA; Triplex- forming oligonucleotides; Catalytic nucleic acids, e.g. ribozymes; Nucleic acids used in co-suppression or gene silencing
    • C12N15/1138—Non-coding nucleic acids modulating the expression of genes, e.g. antisense oligonucleotides; Antisense DNA or RNA; Triplex- forming oligonucleotides; Catalytic nucleic acids, e.g. ribozymes; Nucleic acids used in co-suppression or gene silencing against receptors or cell surface proteins
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies
    • C07K16/18—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans
    • C07K16/28—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants
    • C07K16/2839—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants against the integrin superfamily
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/70—Carbohydrates; Sugars; Derivatives thereof
    • A61K31/7088—Compounds having three or more nucleosides or nucleotides
    • A61K31/7105—Natural ribonucleic acids, i.e. containing only riboses attached to adenine, guanine, cytosine or uracil and having 3'-5' phosphodiester links

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Genetics & Genomics (AREA)
  • Molecular Biology (AREA)
  • Organic Chemistry (AREA)
  • Engineering & Computer Science (AREA)
  • Biochemistry (AREA)
  • General Health & Medical Sciences (AREA)
  • Biomedical Technology (AREA)
  • Medicinal Chemistry (AREA)
  • Immunology (AREA)
  • Biophysics (AREA)
  • General Engineering & Computer Science (AREA)
  • Biotechnology (AREA)
  • Zoology (AREA)
  • Wood Science & Technology (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Epidemiology (AREA)
  • Veterinary Medicine (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Animal Behavior & Ethology (AREA)
  • Public Health (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Physics & Mathematics (AREA)
  • Plant Pathology (AREA)
  • Microbiology (AREA)
  • Measuring Or Testing Involving Enzymes Or Micro-Organisms (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Investigating Or Analysing Biological Materials (AREA)
MX2024007460A 2021-12-17 2022-12-16 Tratamiento de afecciones pulmonares con inhibidores de la subunidad alfa 1 de integrina (itga1). MX2024007460A (es)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
US202163291194P 2021-12-17 2021-12-17
PCT/US2022/081750 WO2023114969A2 (en) 2021-12-17 2022-12-16 Treatment of lung conditions with integrin subunit alpha 1 (itga1) inhibitors

Publications (1)

Publication Number Publication Date
MX2024007460A true MX2024007460A (es) 2024-07-09

Family

ID=85158395

Family Applications (1)

Application Number Title Priority Date Filing Date
MX2024007460A MX2024007460A (es) 2021-12-17 2022-12-16 Tratamiento de afecciones pulmonares con inhibidores de la subunidad alfa 1 de integrina (itga1).

Country Status (7)

Country Link
US (1) US20230192864A1 (https=)
EP (1) EP4448766A2 (https=)
JP (1) JP2024545873A (https=)
CN (1) CN118804976A (https=)
CA (1) CA3240997A1 (https=)
MX (1) MX2024007460A (https=)
WO (1) WO2023114969A2 (https=)

Family Cites Families (6)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
UA73300C2 (en) * 1999-06-01 2005-07-15 Biogen Inc Use of composition containing homolog of antibody antagonizing interaction between integrin with alpha-4 subunit and its ligand for treating fibrosis
WO2006124269A2 (en) * 2005-05-16 2006-11-23 Amgen Fremont Inc. Human monoclonal antibodies that bind to very late antigen-1 for the treatment of inflammation and other disorders
JP2017510552A (ja) * 2014-02-07 2017-04-13 イーフェクター セラピューティクス， インコーポレイテッド 線維性疾患を治療するための方法
EP3458157A4 (en) * 2016-05-19 2020-05-27 Momenta Pharmaceuticals, Inc. METHOD FOR TREATING DISEASES RELATING TO FIBROSE AND SYSTEMIC Sclerosis
WO2018159432A1 (ja) * 2017-03-03 2018-09-07 ロート製薬株式会社 間葉系幹細胞及び医薬組成物
CN111643649A (zh) * 2020-05-20 2020-09-11 博奥生物集团有限公司 防治免疫相关疾病的中药材及其组合物

Also Published As

Publication number Publication date
CN118804976A (zh) 2024-10-18
CA3240997A1 (en) 2023-06-22
WO2023114969A2 (en) 2023-06-22
JP2024545873A (ja) 2024-12-13
US20230192864A1 (en) 2023-06-22
EP4448766A2 (en) 2024-10-23
WO2023114969A3 (en) 2023-07-27

Similar Documents

Publication Publication Date Title
MY203401A (en) Methods and compositions for treating excessive sleepiness
EP3750554A3 (en) Light inhibitors for asthma, lung and airway inflammation, respiratory, interstitial, pulmonary and fibrotic disease treatment
PH12020500197A1 (en) Use of inhaled nitric oxide for the treatment of pulmonary hypertension associated with lung disease
Tallon et al. Airway management in penetrating neck trauma at a Canadian tertiary trauma centre
MX2019012086A (es) Composiciones y métodos para tratar o prevenir trastornos relacionados con la permeabilidad intestinal.
MX2024007460A (es) Tratamiento de afecciones pulmonares con inhibidores de la subunidad alfa 1 de integrina (itga1).
Parikh et al. Airway stenting in excessive central airway collapse
Hata et al. Mini grasping basket forceps for endobronchial foreign body removal in pediatric patients
Tayfun et al. Postintubation laryngotracheal stenosis: assessing the success of surgery
Kong et al. Recurrent pneumothorax following chest tube removal in thoracic stab wounds: a comparative study between end inspiratory versus end expiratory removal techniques at a major trauma centre in South Africa
Podgaetz et al. Intrabronchial valve treatment for prolonged air leak: can we justify the cost?
EA201000337A1 (ru) Модулятор nrg1 для лечения респираторных расстройств
Bhat et al. Bloodless, sutureless circumcision
Linton et al. Embryonal rhabdomyosarcoma masquerading as a left vocal cord granuloma
Abe et al. Long‐term outcome of nitinol stenting to treat asphyxia caused by postpneumonectomy syndrome
WO2021007329A3 (en) Treatment of pulmonary fibrosis using inhibitors of neu1 sialidase
MX2021015553A (es) Inhibidores de arginasa novedosos.
EP4663169A3 (en) Airway support device
Al-Qahtani et al. Ultra percutaneous dilation tracheotomy vs mini open tracheotomy. A comparison of tracheal damage in fresh cadaver specimens
Papavramidis Neuromonitoring during thyroid surgery
Singh et al. Benign laryngeal lesions—a clinicopathological study of eleven years and a case report of pleomorphic lipoma
Nathaniel Glassy et al. Multi-Trajectory Modeling of Caribbean Adolescent Risk Behaviors: Assessing the Impact of Family, Peer, and Neighborhood Factors
Park et al. A Case of Inhalation Burn-Induced Extensive Tracheal Inflammatory Crust Removed by Ventilating Bronchoscopy under Tracheostomy and Extracorporeal Membrane Oxygenation.
PRUITT Intrapulmonary Percussive Ventilation Therapy (IPV): An Essential Solution for Secretion Clearance and Atelectasis.
Wälscher et al. Long-term outcomes and prognostic factors for neuroendocrine G1 and G2 lung tumors